Serial plasmapheresis in a haemophiliac with antibodies to FVIII.

Control of life-threatening bleeding by combined plasmapheresis and immunosuppressive treatment in a haemophiliac with inhibitors.

Life-threatening lingual haemorrhage was successfully treated in a 3-year-old haemophiliac who had a high level of inhibitor in his plasma. Repeated plasma exchange with high-dose factor VIII concentrate led to a cessation of bleeding. Immunosuppressive treatment introduced at the time of plasmapheresis and carried out for 6 weeks seems to have prevented the return of the inhibitor.

Evaluation of inhibitor antibodies in haemophilia A population

Background: Inhibitory antibody to exogenous Factor VIII (FVIII) is a major complication of hemophilia treatment. This study was conducted to determine the prevalence of inhibitor antibody directed against FVIII.Methods: From May 2010 to May 2011, 52 patients with severe hemophilia A admitted in Amirkola Children’s Hospital were evaluated. Those who had abnormal mixing study, antibody against F...

Plasma exchange in non-haemophiliac patients with inhibitors to factor VIIIC.

Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon Resonance

Evidence of antibody isotype/subtype switching may provide prognostic value regarding the state of immune responses to therapeutic proteins, e.g. anti-factor VIII (FVIII) antibodies that develop in many hemophilia A patients, clinically termed "inhibitors". A sensitive, high- information-content surface plasmon resonance (SPR) assay has been developed to quantify IgG subtype distributions and t...

Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.

BACKGROUND The development of neutralizing antibodies, referred to as inhibitors, against factor VIII is a major complication associated with FVIII infusion therapy for the treatment of hemophilia A (HA). Previous studies have shown that a subset of HA patients and a low percentage of healthy individuals harbor non-neutralizing anti-FVIII antibodies that do not elicit the clinical manifestation...